drugset / Trial / NCT00437749
A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Multiple Drug Resistance is the phenomena whereby cells become resistant to a variety of drugs with different mechanisms of action. Drug resistance remains a significant impediment to successful cancer chemotherapy inhibitors have been developed and are currently in clinical trials. CBT-1 is a natural product currently in clinical trials as an inhibitor
Timeline
- Start
- 2001-08
- Primary completion
- 2010-07
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | CBT-1 | Small molecule | 500 mg/m2 | — |
| Comparator | Carboplatin | Small molecule | — | — |
| Comparator | Paclitaxel | Small molecule | 135 mg/m2 | — |